|
Current Clinical Trials in Prostate Cancer
|
 Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.
|
|
Read more
|
| |
|
Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?
|
A new phase 1a/b study examined a total of 49 patients with solid tumors, including those with prostate tumors, with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
|
|
Read more
|
